Printer Friendly

Wockhardt receives approval from United States Food & Drug Administration.

M2 EQUITYBITES-September 18, 2012-Wockhardt receives approval from United States Food & Drug Administration(C)2012 M2 COMMUNICATIONS

Wockhardt, a pharmaceutical and biotechnology major, announced on Monday that it has received final approval from the United States Food & Drug Administration for its latest anti-ulcer drug.

The company has received approval for marketing 15mg and 30 mg delayed release capsules of Lansoprazole, the generic name for the brand Prevacid, which is used in the treatment of peptic ulcers.

Dr. Habil Khorakiwala, Wockhardt Founder Chairman & Group CEO, said "Lansoprazole delayed release formulation is a very challenging product and it once again demonstrates Wockhardt R&D's capability in the NDDS technology space. We have received eight ANDA approvals in the past 30-days and four of them have been products that involved significant technology in formulation."

((Comments on this story may be sent to

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 18, 2012
Previous Article:Beckera[euro](tm)s Hospital Review honours 100 hospitals.
Next Article:Cablevision names Sandra P Kapell as EVP of Human Resources and Administration.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters